Opportunity Information: Apply for RFA DK 11 502
Apply for RFA DK 11 502
- The National Institutes of Health in the food and nutrition health sector is offering a public funding opportunity titled "Limited Competition for Data Coordinating Center (DCC) for NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) (U01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research.
- This funding opportunity was created on Feb 9, 2012 and posted on Feb 9, 2012.
- Applicants must submit their applications by Apr 30, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $1,250,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $900,000.00 in funding.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- Other Eligible Applicants include the following Only institutions which have previously received an award for a DCC under RFA DK 06 504, Announcement of a Limited Competition for the Continuation of the Inflammatory Bowel Disease Genetics Consortium (IBDGC)(U01), are eligible to submit an application in response to this FOA.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
This funding opportunity (RFA-DK-11-502) is a National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) cooperative agreement (U01) to support a single Data Coordinating Center (DCC) for the renewed NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC). The IBDGC has been operating since 2002 with the core mission of finding genetic factors that predispose people to inflammatory bowel disease (IBD). Through collaboration with international genetics groups, the consortium has already helped identify more than 100 IBD susceptibility loci. Even with that progress, the announcement emphasizes that many additional susceptibility genes likely remain undiscovered, and that understanding what these risk variants actually do in the body, meaning how they influence IBD biology and disease mechanisms, is still at an early stage.
The main scientific purpose of the renewed consortium is twofold. First, it aims to continue discovering additional IBD risk variants by leveraging large-scale genetics approaches and consortium-level sample sizes. Second, it seeks to connect genetic discoveries to functional and mechanistic insight by integrating genomics with other "omics" layers, including epigenomics, transcriptomics, proteomics, metabolomics, and related molecular profiling methods. In practice, this signals a shift from gene discovery alone toward a more integrated picture that can link inherited risk to downstream molecular changes and, ultimately, to IBD pathophysiology.
The DCC is positioned as the operational and analytical hub that makes the multi-site consortium function smoothly. The DCC is expected to coordinate collaboration among the Genetic Research Centers (GRCs) that are funded under a companion announcement (RFA-DK-11-032). Beyond general coordination, the DCC role explicitly includes organizing subject enrollment across sites, ensuring that blood and other biospecimens are submitted to centralized repositories, and overseeing key sample processing steps such as extracting DNA from blood and immortalizing cell lines. The DCC is also responsible for orchestrating the flow of information into shared infrastructure: clinical, genetic, and molecular data must be submitted to central databases in a consistent and usable manner. On the back end, the DCC is expected to support and/or conduct analyses of consortium data, which typically involves data cleaning, harmonization across sites, quality control for genetic and molecular datasets, maintaining documentation and data dictionaries, and facilitating cross-center analyses that use combined datasets.
Because this is a cooperative agreement, NIH program staff are generally more involved than in a standard research grant, and the announcement reflects that consortium governance and coordination are central to the award. The DCC program director(s)/principal investigator(s) serves as a voting member of the IBDGC Steering Committee and is expected to follow the operational decisions made by that committee. The DCC also manages the operations of the Steering Committee and other operational committees, which commonly includes planning meetings and calls, preparing agendas and minutes, tracking action items, maintaining timelines and milestones, supporting protocol and policy development, and ensuring that consortium procedures are implemented consistently across participating centers.
This is a limited competition with very narrow eligibility. Only institutions that previously received a DCC award under the prior IBDGC DCC funding opportunity (RFA-DK-06-504) are eligible to apply. That limitation effectively makes this a continuation mechanism intended to retain experienced coordinating infrastructure rather than opening the DCC role to new institutions.
Key administrative details from the announcement include an expected number of awards of one, an estimated total funding amount of about $1,250,000, and an award ceiling of $900,000. There is no cost sharing or matching requirement. The opportunity was posted February 9, 2012, with an original and current closing date of April 30, 2012, and an archive date of May 31, 2012. The CFDA number listed is 93.847 (Diabetes, Digestive, and Kidney Diseases Extramural Research). The activity is categorized under health, and the sponsoring agency is the NIH.
In plain terms, this FOA funds the central coordinating organization that keeps a large, multi-center IBD genetics and multi-omics consortium running: standardizing enrollment and sample handling, ensuring biospecimens and data reach the right repositories and databases, supporting quality control and integrated analyses, and providing the committee management and governance support needed to move discovery and translation forward across multiple participating research centers.
Frequently Asked Questions (FAQs)
What is the funding opportunity number and title?
The funding opportunity is RFA-DK-11-502. It supports a single Data Coordinating Center (DCC) for the renewed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Inflammatory Bowel Disease Genetics Consortium (IBDGC).
Which agency is offering this opportunity?
This is a National Institutes of Health (NIH) opportunity sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
What type of award mechanism is used?
The award mechanism is a cooperative agreement (U01). This structure emphasizes active involvement by NIH program staff and coordinated consortium governance.
What is being funded under this FOA?
This FOA funds the central Data Coordinating Center (DCC) that serves as the operational and analytical hub for a multi-site IBD genetics and multi-omics consortium. The DCC is expected to coordinate consortium activities across participating sites and support consistent handling of enrollment, biospecimens, data submission, and analyses.
How many awards are expected?
One award is expected.
What is the estimated total funding amount and the award ceiling?
The estimated total funding amount is about $1,250,000, and the award ceiling is $900,000.
Is cost sharing or matching required?
No. There is no cost sharing or matching requirement.
Who is eligible to apply?
Eligibility is limited. Only institutions that previously received a DCC award under the prior IBDGC DCC funding opportunity (RFA-DK-06-504) are eligible to apply.
Is this an open competition?
No. It is a limited competition with narrowly defined eligibility tied to the prior IBDGC DCC award (RFA-DK-06-504).
What is the overall mission of the IBD Genetics Consortium (IBDGC)?
The IBDGC has operated since 2002 with the core mission of identifying genetic factors that predispose people to inflammatory bowel disease (IBD). The consortium has collaborated with international genetics groups and has helped identify more than 100 IBD susceptibility loci.
What scientific goals are emphasized for the renewed consortium?
The renewed consortium has two main scientific aims: (1) continue discovering additional IBD risk variants using large-scale genetics approaches and large consortium sample sizes, and (2) connect genetic findings to functional and mechanistic insight by integrating genomics with other omics layers (such as epigenomics, transcriptomics, proteomics, and metabolomics).
How does this FOA reflect a shift in research direction?
While gene discovery remains a priority, the FOA highlights a move toward integrating genetics with multi-omics data to better understand what risk variants do biologically and how they influence IBD mechanisms and pathophysiology.
What role does the DCC play within the consortium?
The DCC functions as the operational and analytical hub for a multi-center program. It is responsible for coordinating collaboration among participating Genetic Research Centers (GRCs), standardizing processes across sites, and supporting the shared infrastructure needed for enrollment, biospecimen handling, data submission, quality control, and integrated analyses.
What other consortium components are referenced in this announcement?
The DCC is expected to coordinate with Genetic Research Centers (GRCs) that are funded under a companion announcement (RFA-DK-11-032).
What responsibilities does the DCC have for subject enrollment?
The DCC is expected to organize subject enrollment across sites, supporting consistent operational processes across participating centers.
What responsibilities does the DCC have for biospecimens?
The DCC is expected to ensure that blood and other biospecimens are submitted to centralized repositories and to oversee key sample processing steps, including extracting DNA from blood and immortalizing cell lines.
What are the DCC responsibilities for data submission and central databases?
The DCC is responsible for orchestrating submission of clinical, genetic, and molecular data to central databases in a consistent and usable manner, supporting harmonization across sites and ensuring shared infrastructure receives well-documented datasets.
What analytical and data management support is the DCC expected to provide?
The DCC is expected to support and/or conduct analyses of consortium data, which typically includes data cleaning, cross-site harmonization, quality control of genetic and molecular datasets, maintaining documentation and data dictionaries, and facilitating cross-center analyses that use combined datasets.
What does the cooperative agreement structure mean for governance?
As a cooperative agreement, NIH program staff are generally more involved than in a standard research grant, and consortium governance and coordination are central. The DCC leadership participates directly in consortium decision-making through the Steering Committee structure described in the FOA.
What is the DCC Program Director/Principal Investigator (PD/PI) role in consortium governance?
The DCC PD/PI serves as a voting member of the IBDGC Steering Committee and is expected to follow the operational decisions made by that committee.
What committee management responsibilities are assigned to the DCC?
The DCC manages operations of the Steering Committee and other operational committees. This commonly includes planning meetings and calls, preparing agendas and minutes, tracking action items, maintaining timelines and milestones, supporting protocol and policy development, and helping ensure consortium procedures are implemented consistently across sites.
What does the FOA say about the current state of IBD genetics research?
It notes that the consortium has helped identify more than 100 IBD susceptibility loci, but also emphasizes that many additional susceptibility genes likely remain undiscovered and that the functional understanding of how risk variants influence IBD biology is still at an early stage.
What kinds of omics data are specifically mentioned for integration?
The FOA mentions integrating genomics with epigenomics, transcriptomics, proteomics, metabolomics, and related molecular profiling approaches.
What is the CFDA number associated with this opportunity?
The CFDA number listed is 93.847 (Diabetes, Digestive, and Kidney Diseases Extramural Research).
What is the posting date and the closing date for this FOA?
The opportunity was posted on February 9, 2012. The original and current closing date is April 30, 2012.
When was the opportunity archived?
The archive date listed is May 31, 2012.
What is the activity area/category for this opportunity?
The activity is categorized under health.
In plain terms, what does this grant support?
It supports the central coordinating organization that keeps a large, multi-center IBD genetics and multi-omics consortium running: standardizing enrollment and sample handling, ensuring biospecimens and data reach central repositories and databases, supporting quality control and integrated analyses, and providing the committee and governance support needed to move the consortium forward.
Browse more opportunities from the same category: Food and Nutrition Health
Next opportunity: CESU Paleontology Collections Management, Fairbanks, Alaska
Previous opportunity: NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) Genetic Research Centers (GRCs) (U01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DK 11 502
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DK 11 502) also looked into and applied for these:
| Funding Opportunity |
|---|
| The Collaborative Islet Transplantation Registry (UC4) Apply for RFA DK 12 002 Funding Number: RFA DK 12 002 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $530,000 |
| NIDDK Short Term Education Program for Underrepresented Persons (STEP UP) (R25) Apply for RFA DK 12 005 Funding Number: RFA DK 12 005 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $158,000 |
| The Human Islet Distribution Coordinating Center (UC4) Apply for RFA DK 12 001 Funding Number: RFA DK 12 001 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $2,000,000 |
| Secondary Analyses in Obesity, Diabetes and Digestive and Kidney Diseases (R21) Apply for PA 12 125 Funding Number: PA 12 125 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $200,000 |
| Pilot and Feasibility Clinical Research Grants in Diabetes, and Endocrine and Metabolic Diseases (R21) Apply for PA 12 157 Funding Number: PA 12 157 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $200,000 |
| Translational Research to Improve Obesity and Diabetes Outcomes (R18) Apply for PAR 12 172 Funding Number: PAR 12 172 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Planning Grants for Translational Research to Improve Obesity and Diabetes Outcomes (R34) Apply for PAR 12 173 Funding Number: PAR 12 173 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $150,000 |
| Promoting Organ and Tissue Donation Among Diverse Populations (R01) Apply for RFA DK 12 006 Funding Number: RFA DK 12 006 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $150,000 |
| Limited Competition for the Continuation of the Halt Polycystic Kidney Disease Trials Data Coordinating Center (DCC) (U01) Apply for RFA DK 12 505 Funding Number: RFA DK 12 505 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Limited Competition for the Continuation of Look AHEAD (Action for Health in Diabetes) Consortium (U01) Apply for RFA DK 12 502 Funding Number: RFA DK 12 502 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Renal Function and Chronic Kidney Disease in Aging (R01) Apply for PA 12 211 Funding Number: PA 12 211 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| George M. OBrien Kidney Research Core Centers (P30) Apply for RFA DK 12 008 Funding Number: RFA DK 12 008 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $750,000 |
| Research Enhancement for NIDDK Hematology Grantees (Admin Supp) Apply for PA 12 242 Funding Number: PA 12 242 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| New Technologies for the Study of Lymphatics in the Digestive and Urinary Systems (R43/R44) Apply for PA 12 258 Funding Number: PA 12 258 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $150,000 |
| Lymphatics in Health and Disease in the Digestive, Urinary, Cardiovascular and Pulmonary Systems (R01) Apply for PAR 12 259 Funding Number: PAR 12 259 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $250,000 |
| Lymphatics in Health and Disease in the Digestive, Cardiovascular and Pulmonary Systems (R21) Apply for PAR 12 260 Funding Number: PAR 12 260 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $125,000 |
| Ancillary Studies to Major Ongoing Clinical Research Studies to Advance Areas of Scientific Interest within the Mission of the NIDDK (R01) Apply for PAR 12 265 Funding Number: PAR 12 265 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Limited Competition for the Continuation of the Assessment, Serial Evaluation and Subsequent Sequelae of Acute Kidney Injury (ASSESS AKI) Study (U01) Apply for RFA DK 12 509 Funding Number: RFA DK 12 509 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Pilot Studies of Candidate Therapies for Chronic Kidney Disease (CKD) (U01) Apply for RFA DK 12 016 Funding Number: RFA DK 12 016 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Expansion of Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) (U01) Apply for RFA DK 12 017 Funding Number: RFA DK 12 017 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DK 11 502", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.